Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent,~* Male or female patients, 18 to 75 years of age,~* Confirmed clinico-pathological diagnosis of eosinophilic esophagitis (EoE) according to established diagnostic criteria~* Active symptomatic and histological EoE,~* A documented trial with proton pump inhibitors (PPIs) in order to rule out PPI-responsive esophageal eosinophilia,~* Negative pregnancy test in females of childbearing potential at baseline visit.~Exclusion Criteria:~* Clinical and endoscopic signs of gastroesophageal reflux disease (GERD),~* History of abnormal results in case of an optionally performed pH-monitoring of the distal esophagus,~* Patients with PPI-responsive esophageal eosinophilia~* Achalasia, scleroderma esophagus, or systemic sclerosis,~* Other clinically evident causes than EoE for esophageal eosinophilia,~* Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection \[candida esophagitis\]),~* Any relevant systemic disease (e.g., AIDS, active tuberculosis),~* If careful medical monitoring is not ensured: cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection,~* Liver cirrhosis or portal hypertension,~* History of cancer in the last five years,~* History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit,~* Upper gastrointestinal bleeding within 8 weeks prior to screening visit,~* Existing or intended pregnancy or breast-feeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: EXPERIMENTAL): Budesonide 1mg orodispersible tablet twice daily
- Placebo (Type: PLACEBO_COMPARATOR): Placebo orodispersible tablet twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).